Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00375830
Recruitment Status : Completed
First Posted : September 13, 2006
Results First Posted : November 8, 2019
Last Update Posted : November 25, 2019
Sponsor:
Information provided by (Responsible Party):
Andrei Iagaru, Stanford University

Brief Summary:
This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.

Condition or disease Intervention/treatment Phase
Cancer Procedure: Bone scan Drug: 99mTc-methyl diphosphonate Procedure: Positron Emission Tomography (PET) scan Drug: 18F-Fludeoxyglucose (18F-FDG) Procedure: Computed Tomography (CT) scan Drug: 18F-Sodium Fluoride (18F-NaF) Procedure: Whole Body Magnetic Resonance Imaging (WB-MRI) scan Drug: Gadopentetate dimeglumine Drug: Gadofosveset Drug: Gadobutrol Phase 2

Detailed Description:

Eligible participants had previously received a bone scan using the radiolabel 99mTc-methyl diphosphonate (t99-MDP) as part of their regular medical care.

18F-NaF and 18F-FDG are radioactive substances (radiolabels) that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI). PET/WBMRI is a combination procedure that combines the detailed PET images of areas inside the body from PET with the WBMRI scans, and may help find and diagnose skeletal metastases in patients with breast or prostate cancer. It is not yet known whether 18F-NaF/18F-FDG PET/WBMRI is better than standard imaging methods in detecting skeletal metastases.

Eligible participants diagnosed with breast/prostate cancers and who have had 99mTc MDP bone scanning as part of their routine care are recruited and enrolled. Participants then receive an 18F-NaF/18F-FDG positron emission tomography (PET)/ WBMRI combination scan.

The PET/MRI scans will be interpreted by 2 American Board Nuclear Medicine (ABNM)-certified physicians and 2 American Board of Radiology (ABR)-certified radiologists, all with significant clinical experience, who are blinded to the subjects' medical history and the results of other imaging modalities.

The scans will be analyzed and compared against each other, with a consensus read will be obtained for each scan. Characterization of lesions as true-positive, true-negative, false-positive or false-negative will be done through a combination of clinical follow-up, imaging follow-up and/or histopathology findings. An overall diagnosis based on each scan will be determined on a 5-point scale (1=benign, 2=likely benign, 3=uncertain, 4=likely malignant, 5=malignant) to conduct a receiver operating characteristic (ROC) analysis.

If the diagnosis is positive for metastases on any of the scans, the investigator will identify the number of lesions and locations of positivity, and record this information.

Clinical is obtained at about 12 months after the initial scans.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 114 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Actual Study Start Date : January 2006
Actual Primary Completion Date : April 17, 2017
Actual Study Completion Date : March 14, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Nuclear Scans

Arm Intervention/treatment
Experimental: Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans
Preliminary pilot assessment to confirm feasibility & improved diagnostic accuracy of the combined 18F-NaF CT & 18F-FDG PET scan procedures, as compared to the regular medical care procedure, 99mTc MDP bone scans.
Procedure: Bone scan
Scan to diagnose a number of bone conditions including cancer or metastasis
Other Name: Bone scintigraphy

Drug: 99mTc-methyl diphosphonate
Radiolabel for bone scan procedures
Other Names:
  • 99mTc-methylene diphosphonate
  • Technetium 99mTc medronate
  • 99mTc-MDP
  • t99-MDP

Procedure: Positron Emission Tomography (PET) scan
Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F

Drug: 18F-Fludeoxyglucose (18F-FDG)
Radiolabel for positron emission tomography scan procedures
Other Names:
  • 2-Deoxy-2-(18F)Fluoro-D-Glucose
  • 2-F18-Fluoro-2-deoxy-D-glucose
  • 2-F18-Fluoro-2-deoxyglucose
  • 18F 2-Fluoro-2-deoxy-D-Glucose
  • Fludeoxyglucose F-18
  • Fluorodeoxyglucose F18

Procedure: Computed Tomography (CT) scan
Scan to detect & analyze X-rays
Other Names:
  • Computerized Axial Tomograph (CAT) scan
  • Computer-aided Tomography (CAT) scan

Drug: 18F-Sodium Fluoride (18F-NaF)
Radiolabel for CT and PET scans, & as a contrast agent for MRI scans.
Other Name: 18F-Sodium Fluorine

Drug: Gadopentetate dimeglumine
A gadolinium-based contrast agent for MRI
Other Name: Magnevist

Experimental: Cohort 2 WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans
Assessment to define the accuracy of the combined 18F-NaF CT & 18F-FDG PET/CT scan procedures compared to 99mTc MDP bone scan.
Procedure: Bone scan
Scan to diagnose a number of bone conditions including cancer or metastasis
Other Name: Bone scintigraphy

Drug: 99mTc-methyl diphosphonate
Radiolabel for bone scan procedures
Other Names:
  • 99mTc-methylene diphosphonate
  • Technetium 99mTc medronate
  • 99mTc-MDP
  • t99-MDP

Procedure: Positron Emission Tomography (PET) scan
Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F

Drug: 18F-Fludeoxyglucose (18F-FDG)
Radiolabel for positron emission tomography scan procedures
Other Names:
  • 2-Deoxy-2-(18F)Fluoro-D-Glucose
  • 2-F18-Fluoro-2-deoxy-D-glucose
  • 2-F18-Fluoro-2-deoxyglucose
  • 18F 2-Fluoro-2-deoxy-D-Glucose
  • Fludeoxyglucose F-18
  • Fluorodeoxyglucose F18

Procedure: Computed Tomography (CT) scan
Scan to detect & analyze X-rays
Other Names:
  • Computerized Axial Tomograph (CAT) scan
  • Computer-aided Tomography (CAT) scan

Drug: 18F-Sodium Fluoride (18F-NaF)
Radiolabel for CT and PET scans, & as a contrast agent for MRI scans.
Other Name: 18F-Sodium Fluorine

Procedure: Whole Body Magnetic Resonance Imaging (WB-MRI) scan
Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields & radio waves to generate images of the organs in the body.

Drug: Gadofosveset
A gadolinium-based contrast agent for MRI
Other Name: Ablavar

Drug: Gadobutrol
A gadolinium-based contrast agent for MRI
Other Name: Gadavist

Experimental: Cohort 3 Combined 18F-NaF / 18F-FDG PET/WB-MRI scan
Assessment to define the utility of 18F-NaF & 18F-FDG as the radiolabels in a single combined PET / WB-MRI procedure.
Procedure: Bone scan
Scan to diagnose a number of bone conditions including cancer or metastasis
Other Name: Bone scintigraphy

Drug: 99mTc-methyl diphosphonate
Radiolabel for bone scan procedures
Other Names:
  • 99mTc-methylene diphosphonate
  • Technetium 99mTc medronate
  • 99mTc-MDP
  • t99-MDP

Procedure: Positron Emission Tomography (PET) scan
Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F

Drug: 18F-Fludeoxyglucose (18F-FDG)
Radiolabel for positron emission tomography scan procedures
Other Names:
  • 2-Deoxy-2-(18F)Fluoro-D-Glucose
  • 2-F18-Fluoro-2-deoxy-D-glucose
  • 2-F18-Fluoro-2-deoxyglucose
  • 18F 2-Fluoro-2-deoxy-D-Glucose
  • Fludeoxyglucose F-18
  • Fluorodeoxyglucose F18

Drug: 18F-Sodium Fluoride (18F-NaF)
Radiolabel for CT and PET scans, & as a contrast agent for MRI scans.
Other Name: 18F-Sodium Fluorine

Procedure: Whole Body Magnetic Resonance Imaging (WB-MRI) scan
Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields & radio waves to generate images of the organs in the body.

Drug: Gadofosveset
A gadolinium-based contrast agent for MRI
Other Name: Ablavar

Drug: Gadobutrol
A gadolinium-based contrast agent for MRI
Other Name: Gadavist




Primary Outcome Measures :
  1. Cohort 1 - NaF PET/CT vs 99mTc-MDP Bone Scintigraphy [ Time Frame: 30 days ]
    The medical value of 18F-sodium fluoride (NaF) positron emission tomography / computed tomography (PET/CT) vs 99mTc-methylene diphosphonate (MDP) bone scintigraphy was assessed on the basis of the radiation oncologist's medical assessment of image quality and detected extent of disease, for each participant. Per protocol, the data were collected and the outcome is reported for Cohort 1 only. The outcome is reported as the number of participants for whom the medical value of the image was superior for 18F-NaF vs 99mTc-MDP bone scintigraphy ("18F-NaF > 99mTc-MDP"), the same between both scans ("18F-NaF = 99mTc-MDP"), or inferior for 18F-NaF vs 99mTc-MDP bone scintigraphy ("18F-NaF < 99mTc-MDP").


Secondary Outcome Measures :
  1. Cohort 1 - 18F-NaF PET/CT vs 18F-FDG PET/CT [ Time Frame: 30 days ]
    The medical value of 18F-sodium fluoride (NaF) positron emission tomography / computed tomography (PET/CT) vs 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) was assessed on the basis of the radiation oncologist's medical assessment of image quality and detected extent of disease, for each participant diagnosed with osseous (skeletal) metastases. Per protocol, the data were collected and the outcome is reported for Cohort 1 only. The outcome is reported as the number of participants for whom the medical value of the image was superior for 18-NaF PET/CT compared to 18F-FDG PET/CT, the same between both scans, or inferior for 18-NaF PET/CT compared to 18F-FDG PET/CT. The outcome result is represented as a number without dispersion.

  2. Cohort 1 - Whole-body MRI vs 18F-NaF PET/CT [ Time Frame: 30 days ]

    The medical value of whole body magnetic imaging resonance (WB-MRI) vs 18F-sodium fluoride (NaF) positron emission tomography / computed tomography (PET/CT) was assessed on the basis of which scan detected the greater number of tumor lesions in each participant. Per protocol, the data were collected and the outcome is reported for Cohort 1 only. The outcome is reported as the number of participants for whom lesions detected by WB MRI was > 18F-NaF PET/CT; equal to 18F-NaF PET/CT; or < 18F-NaF PET/CT. The outcome result is represented as a number without dispersion.

    8 analyzed 5 2

    1


  3. Cohort 1 - Whole-body MRI vs 18F-FDG PET/CT [ Time Frame: 30 days ]
    The medical value of whole body magnetic imaging resonance (WB-MRI) vs 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) was assessed on the basis of which scan detected the greater number of tumor lesions in each participant. Per protocol, the data were collected and the outcome is reported for Cohort 1 only. The outcome is reported as the number of participants for whom lesions detected by WB MRI was > 18F-FDG PET/CT; equal to to 18F-FDG PET/CT; or < 18F-FDG PET/CT. The outcome result is represented as a number without dispersion.

  4. Cohort 1 - Detection of Osseous (Skeletal) Metastases by 18F-NaF and 18F-FDG PET/CT [ Time Frame: 30 days ]
    The ability of 18F-sodium fluoride (NaF) and 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) to detect osseous (skeletal) metastases was assessed. Per protocol, the data were collected and the outcome is reported for Cohort 1 only. The outcome is reported as the number of Cohort 1 participants for whom osseous metastases were detected, a number without dispersion.

  5. Cohort 2 - 18F-NaF/18F-FDG PET/CT vs Whole-body MRI for Detection of Extraskeletal Lesions [ Time Frame: 30 days ]

    Sensitivity; positive predictive value (PPV); and accuracy for the detection of extraskeletal lesions was assessed for 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) and for whole body magnetic imaging resonance (WB-MRI).

    • Sensitivity is a percentage that defines the proportion of true positive participants with the disease in a total group of participants.
    • PPV is the probability that participants with a positive screening test truly have the disease.
    • Accuracy is the proportion of true results (both true positives and true negatives) among the total number of cases examined.

    Per protocol, the data were collected and the outcome is reported for Cohort 2 only. Sensitivity, PPV, and accuracy are reported as a percentage, a number without dispersion. Higher numbers represent better detection.


  6. Cohort 2 - 18F-NaF/18F-FDG vs Whole-body MRI for Detection of Skeletal Lesions [ Time Frame: 30 days ]
    Sensitivity and accuracy for the detection of skeletal lesions was assessed for 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) and for whole body magnetic imaging resonance (WB-MRI). Per protocol, the data were collected and the outcome is reported for Cohort 2 only. Sensitivity and accuracy are reported as a percentage, a number without dispersion. Higher numbers represent better detection.

  7. Cohort 2 - 18F-NaF/18F-FDG vs 99mTc-MDP Bone Scintigraphy for Detection of Skeletal Lesions [ Time Frame: 30 days ]
    Sensitivity and accuracy for the detection of skeletal lesions was assessed for 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) and for 99mTc-methylene diphosphonate (MDP) bone scintigraphy. Per protocol, the data were collected and the outcome is reported for Cohort 2 only. Sensitivity and accuracy are reported as a percentage, a number without dispersion. Higher numbers represent better detection.

  8. Cohort 2 - Overall Sensitivity and Accuracy for 18F-NaF/18F-FDG vs Whole-body MRI [ Time Frame: 30 days ]
    Overall sensitivity and accuracy for the detection of tumor lesions was assessed for 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) and for whole body magnetic imaging resonance (WB-MRI). Per protocol, the data were collected and the outcome is reported for Cohort 2 only. Sensitivity and accuracy are reported as a percentage, a number without dispersion. Higher numbers represent better detection.

  9. Cohort 2 - Overall Sensitivity and Accuracy for 18F-NaF/18F-FDG vs Whole-body MRI/99mTc-MDP Bone Scintigraphy [ Time Frame: 30 days ]
    Overall sensitivity and accuracy for the detection of tumor lesions was assessed for 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) and for 99mTc-methylene diphosphonate (MDP) bone scintigraphy. Per protocol, the data were collected and the outcome is reported for Cohort 2 only. Sensitivity and accuracy are reported as a percentage, a number without dispersion. Higher numbers represent better detection.

  10. Cohort 3 - Skeletal Lesions Identified by 99mTc MDP WBBS vs 18F-NaF / 18F-FDG PET/MRI [ Time Frame: 30 days ]
    Participants in Cohort 3 received 99mTc-methylene diphosphonate (MDP) whole-body bone scintigraphy (WBBS) and 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / magnetic imaging resonance (PET/MRI) scans. On the basis of the scans, participants with skeletal lesions were identified. The outcome is reported as the number of Cohort 3 participants for whom skeletal lesions were identified by each scan methodology, a number without dispersion.

  11. Cohort 3 - Total Skeletal Lesions Identified, Tc-99m MDP WBBS vs 18F-NaF / 18F-FDG PET/MRI [ Time Frame: 30 days ]
    Participants in Cohort 3 received 99mTc-methylene diphosphonate (MDP) whole-body bone scintigraphy (WBBS) and 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / magnetic imaging resonance (PET/MRI) scans. On the basis of the scans, the total number skeletal lesions identified in the participants was determined. The outcome is reported as the total number skeletal lesions identified by each scan methodology, a number without dispersion.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

All patients were enrolled after receiving a regular medical care bone scan using the radiolabel 99mTc-methyl diphosphonate (t99-MDP).

INCLUSION CRITERIA

  • ≥ 18 years old at the time of the drug administration
  • ≥ Stage 3 breast cancer OR ≥ stage 2 prostate cancer OR prostate-specific antigen (PSA) > 10 micrograms/L OR recurrent breast or prostate cancer
  • Capable of complying with study procedures
  • Able to remain still for duration of imaging procedure (about one hour)
  • Written informed consent

EXCLUSION CRITERIA

  • Pregnant or nursing
  • Metallic implants that contraindicate MRI
  • Renal function impairment that contraindicates MRI

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00375830


Locations
Layout table for location information
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Layout table for investigator information
Principal Investigator: Andrei Iagaru, MD Stanford University
  Study Documents (Full-Text)

Documents provided by Andrei Iagaru, Stanford University:
Informed Consent Form  [PDF] April 26, 2019

Publications of Results:
Layout table for additonal information
Responsible Party: Andrei Iagaru, Professor of Radiology (Nuclear Medicine), Stanford University
ClinicalTrials.gov Identifier: NCT00375830    
Other Study ID Numbers: IRB-03778
96754 ( Other Identifier: Stanford University Alternate IRB Approval Number )
BONE0001 ( Other Identifier: OnCore )
First Posted: September 13, 2006    Key Record Dates
Results First Posted: November 8, 2019
Last Update Posted: November 25, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Neoplasms
Pathologic Processes
Diphosphonates
Methylene diphosphonate
Listerine
Deoxyglucose
Fluorides
Sodium Fluoride
Fluorodeoxyglucose F18
Technetium Tc 99m Medronate
Cariostatic Agents
Protective Agents
Physiological Effects of Drugs
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents, Local
Anti-Infective Agents
Antimetabolites
Antiviral Agents
Bone Density Conservation Agents